Arca
Skip to content
Tools
Tools

F8: Coagulation factor VIII

Factor VIII, along with calcium and phospholipid, acts as a cofactor for F9/factor IXa when it converts F10/factor X to the activated form, factor Xa.

  • Drugs that act on it: 16
  • Approved: 13
  • In phases 1 to 3: 3
  • Sponsors: 12

Who is on it, and how far along

Every drug ChEMBL records acting on F8, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Protein or peptide 11
  • Other 5

Approved13

  • Moroctocog alfa
  • Octocog alfa
  • Human coagulation factor viii
  • Efanesoctocog alfa
  • Damoctocog alfa pegol
  • Turoctocog alfa
  • Turoctocog alfa pegol
  • Efmoroctocog alfa
  • Susoctocog alfa
  • Antihemophilic factor, pegylated (mw 20000) human sequence recombinant
  • Drotrecogin alfa (activated)
  • Lonoctocog alfa
  • Simoctocog alfa

Phase 32

Phase 21

  • TB-402

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • AryoGen Pharmed Co.16%
    • Hangzhou Gensciences Biopharmaceutical Co., Ltd.16%
    • Octapharma16%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 13 of 16 act as: Coagulation factor VIII exogenous protein; the rest name their own mechanism.
    Moroctocog alfaApprovedPfizerProtein or peptideExogenous protein72
    Octocog alfaApprovedSanofiProtein or peptideExogenous protein72
    Human coagulation factor viiiApprovedHangzhou Gensciences Biopharmaceutical Co., Ltd.OtherExogenous protein24
    Efanesoctocog alfaApprovedSanofiProtein or peptideExogenous protein10
    Damoctocog alfa pegolApprovedBayerProtein or peptideExogenous protein5
    Turoctocog alfaApprovedNovo NordiskProtein or peptideExogenous protein2
    Turoctocog alfa pegolApprovedNovo NordiskProtein or peptideExogenous protein2
    Efmoroctocog alfaApprovedAryoGen Pharmed Co.Protein or peptideExogenous protein1
    Susoctocog alfaApprovedTakeda Pharmaceuticals USAProtein or peptideExogenous protein1
    Antihemophilic factor, pegylated (mw 20000) human sequence recombinantApprovedTakeda Pharmaceuticals USAOtherExogenous protein0
    Drotrecogin alfa (activated)ApprovedEli LillyProtein or peptideInhibitorCoagulation factor VIII inhibitor0
    Lonoctocog alfaApprovedCSLProtein or peptideExogenous protein0
    Simoctocog alfaApprovedOctapharmaProtein or peptideExogenous protein0
    Giroctocogene fitelparvovecPhase 3PfizerGeneExogenous geneCoagulation factor VIII exogenous gene2
    Omfiloctocog alfaPhase 3Sinocelltech Ltd.OtherExogenous protein0
    TB-402Phase 2ThromboGenicsOtherInhibitorCoagulation factor VIII inhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 31 in all, from ClinicalTrials.gov.
    A Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate Hemophilia A or B Without InhibitorsMoroctocog alfa, Octocog alfaPhase 3RecruitingPfizerNov 9, 2026
    A Study to Describe Patient REal-world FitusiRan ExpeRienceMoroctocog alfa, Octocog alfa—Not yet recruitingSanofiOct 26, 2026
    Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and ChildrenMoroctocog alfa, Octocog alfaPhase 3RecruitingHoffmann-La RocheSep 24, 2026
    Efanesoctocog Prophylaxis Or The Optimization Of Treatment: Real-World Experience Of Taylorizing Clotting Therapy In Hemophilia AEfanesoctocog alfa, Moroctocog alfa, Octocog alfa—Not yet recruitingNantes University HospitalSep 21, 2026
    Prevalence of Inhibitor Development in Hemophilia A Patients Receiving Coageight: A Multicenter Cross-sectional Observational StudyEfmoroctocog alfa, Moroctocog alfa, Octocog alfa—Not yet recruitingAryoGen Pharmed Co.Aug 28, 2026
    A First-in Human Study of ARD001 in Healthy Volunteers and People With Hemophilia AHuman coagulation factor viiiPhase 1 / Phase 2RecruitingArditus Pte LtdAug 26, 2026
    Study of Surgical Practices in Hemophilia A Patients Treated With Efanesoctocog Alfa (Altuvoct®)Efanesoctocog alfa, Moroctocog alfa, Octocog alfa—RecruitingHospices Civils de LyonJul 23, 2026
    TG-INSIGHT With Joint POCUS, Hemostatic Potential in Patients With Severe Hemophilia A on Novel Replacement and Substitution FVIII TherapiesMoroctocog alfa, Octocog alfa—RecruitingUniversity of Texas Southwestern Medical CenterJul 9, 2026
    Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.Human coagulation factor viii, Moroctocog alfa, Octocog alfaPhase 3Active, not recruitingHangzhou Gensciences Biopharmaceutical Co., Ltd.Jul 6, 2026
    Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand TreatmentHuman coagulation factor viiiPhase 3Active, not recruitingHangzhou Gensciences Biopharmaceutical Co., Ltd.Jun 23, 2026
    A Prospective Assessment of Bone Health in Patients With Severe Hemophilia A on Factor VIII vs Factor Mimetic Prophylaxis (Efa Emi Bone Health Study)Efanesoctocog alfa—RecruitingArkansas Children's Hospital Research InstituteMay 12, 2026
    Post Approval Phase 4 Study to Learn More About How Safe Octocog Alfa is, and How Well it Works in Patients With Severe Hemophilia A in IndiaHuman coagulation factor viii—Not yet recruitingBayerMar 3, 2026
    A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia AHuman coagulation factor viiiPhase 3RecruitingHoffmann-La RocheFeb 18, 2026
    A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)Human coagulation factor viiiPhase 3RecruitingTakedaAug 19, 2025
    An Observational Study to Learn More About How Well Damoctocog Alfa Pegol Works in Children With Hemophilia ADamoctocog alfa pegol—RecruitingBayerJul 28, 2025
    Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial HypertrophyEfanesoctocog alfaPhase 4RecruitingSanofiApr 24, 2025
    Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog AlfaEfanesoctocog alfaPhase 4Active, not recruitingSwedish Orphan BiovitrumApr 23, 2025
    Low Dose Emicizumab vs Low Dose Factor VIII in Prophylaxis in Hemophilia A PatientsHuman coagulation factor viiiPhase 2 / Phase 3Not yet recruitingDhaka Medical CollegeApr 22, 2025
    A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa ProphylaxisEfanesoctocog alfaPhase 4Active, not recruitingSwedish Orphan BiovitrumDec 31, 2024
    An Open-label Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of SKP-0141 for the Treatment and Prophylaxis in Severe Hemophilia a PatientsHuman coagulation factor viiiPhase 3Not yet recruitingSK Plasma Co., Ltd.Dec 18, 2024
    Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog AlfaEfanesoctocog alfaPhase 3Active, not recruitingSwedish Orphan BiovitrumDec 4, 2024
    A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in TaiwanEfanesoctocog alfa—Active, not recruitingSanofiNov 12, 2024
    A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia ASusoctocog alfa—RecruitingTakedaJun 17, 2024
    A Study to Learn More About the Safety of Damoctocog-alfa-pegol When Used in Routine Medical Care in Korean Participants With Hemophilia ADamoctocog alfa pegol—RecruitingBayerJan 25, 2024
    An Observational Study Called JOIHA to Learn More About How Well the Treatment With Jivi Works to Prevent Problems With Joints in Adults With Hemophilia A.Damoctocog alfa pegol—Active, not recruitingBayerDec 8, 2022
    Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B RespectivelyGiroctocogene fitelparvovecPhase 3RecruitingPfizerOct 6, 2022
    Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa PegolTuroctocog alfa, Turoctocog alfa pegol—Enrolling by invitationNovo Nordisk A/SDec 23, 2020
    A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®Turoctocog alfa, Turoctocog alfa pegol—Enrolling by invitationNovo Nordisk A/SOct 5, 2020
    Study to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Jivi Regularly at Their Treating Doctors to Prevent BleedingDamoctocog alfa pegol—Active, not recruitingBayerJul 8, 2020
    Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A AdultsGiroctocogene fitelparvovecPhase 3Active, not recruitingPfizerApr 30, 2020
    Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia ADamoctocog alfa pegol—Active, not recruitingBayerApr 30, 2019

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    • Thrombophilia, X-linked, due to factor 8 defect0.66
    • Immune system disorder0.57
    • Severe hemophilia A0.55
    • Mild hemophilia A0.52
    • Abnormality of coagulation0.49
    • Hereditary disease0.47

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3143, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P00451, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.